Stock Analysis

High Growth Tech Stocks To Watch In February 2025

As global markets navigate a landscape marked by mixed corporate earnings and competitive pressures in the AI sector, U.S. stocks have experienced volatility, with notable fluctuations in tech-heavy indices like the Nasdaq Composite. In this context, identifying high-growth tech stocks requires careful consideration of companies that can adapt to rapid technological advancements and maintain robust performance despite market uncertainties.

Top 10 High Growth Tech Companies

NameRevenue GrowthEarnings GrowthGrowth Rating
Shanghai Baosight SoftwareLtd21.82%25.22%★★★★★★
Seojin SystemLtd35.41%39.86%★★★★★★
Clinuvel Pharmaceuticals21.39%26.17%★★★★★★
Yggdrazil Group30.20%87.10%★★★★★★
Medley20.95%27.32%★★★★★★
Mental Health TechnologiesLtd25.83%113.12%★★★★★★
Fine M-TecLTD36.52%135.02%★★★★★★
JNTC29.48%104.37%★★★★★★
Dmall29.53%88.37%★★★★★★
Delton Technology (Guangzhou)20.25%29.52%★★★★★★

Click here to see the full list of 1226 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Zealand Pharma (CPSE:ZEAL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zealand Pharma A/S is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines in Denmark, with a market capitalization of DKK52.03 billion.

Operations: Zealand Pharma generates revenue primarily from its biotechnology segment, amounting to DKK76.87 million. The company's business model centers on the development and commercialization of peptide-based medicines.

Zealand Pharma, recently added to the OMX Nordic 40 Index, is navigating a pivotal phase with its innovative drug glepaglutide, targeting short bowel syndrome. Despite facing a setback from the FDA requiring further trials, the company's commitment to R&D is evident as it plans a new Phase 3 trial in 2025. Financially, Zealand reported significant revenue growth at an annual rate of 38.4%, although it currently operates at a loss with recent figures showing a net loss of DKK 266.4 million for Q3 2024. The firm's strategic focus on specialized biotech solutions and its robust pipeline underscore its potential in high-growth markets despite current profitability challenges.

CPSE:ZEAL Earnings and Revenue Growth as at Feb 2025
CPSE:ZEAL Earnings and Revenue Growth as at Feb 2025

Hunan Kylinsec Technology (SHSE:688152)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hunan Kylinsec Technology Co., Ltd. is a company that supplies software products and has a market capitalization of CN¥4.70 billion.

Operations: Kylinsec Technology focuses on the development and supply of software products. The company operates within the technology sector, leveraging its expertise to generate revenue through its software offerings.

Despite recent challenges, including being dropped from the S&P Global BMI Index, Hunan Kylinsec Technology remains a notable contender in the tech sector with its robust revenue growth of 44.9% per year, significantly outpacing the CN market average of 13.5%. This growth is underpinned by substantial R&D investments aimed at fostering innovation and maintaining competitive edge in a rapidly evolving industry. Looking ahead, earnings are expected to surge by an impressive 117% annually over the next three years, positioning Hunan Kylinsec for potential profitability and making it a company to watch as it navigates these transformative periods.

SHSE:688152 Revenue and Expenses Breakdown as at Feb 2025
SHSE:688152 Revenue and Expenses Breakdown as at Feb 2025

TWOWAY Communications (TWSE:8045)

Simply Wall St Growth Rating: ★★★★★★

Overview: TWOWAY Communications, Inc. specializes in the research, development, manufacturing, and sale of indoor and outdoor RF and optical transmission equipment across Taiwan, the United States, Asia, Europe, and other international markets with a market capitalization of NT$12.36 billion.

Operations: The company generates revenue primarily from its Broadband Network Equipment Division, which contributes NT$3.21 billion, and the IOT Division with NT$377.92 million. It also operates a Labor and Other Business Division, adding NT$226.55 million to its revenue streams.

TWOWAY Communications, despite a volatile share price in recent months, showcases robust potential with earnings growth of 51.6% per year and revenue increasing at 38.5% annually—both metrics outpacing the TW market's average growth rates significantly. This performance is bolstered by strategic R&D investments which have not only fueled innovation but also positioned the company well above industry norms in earnings expansion. Recent activities including a successful follow-on equity offering raising TWD 524 million underscore its proactive approach to capital management and market positioning, promising an intriguing trajectory ahead amidst competitive pressures and evolving tech landscapes.

TWSE:8045 Earnings and Revenue Growth as at Feb 2025
TWSE:8045 Earnings and Revenue Growth as at Feb 2025

Next Steps

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

The New Payments ETF Is Live on NASDAQ:

Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.

Explore how this launch could reshape portfolios

Sponsored Content

Valuation is complex, but we're here to simplify it.

Discover if Zealand Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About CPSE:ZEAL

Zealand Pharma

A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.

Excellent balance sheet with proven track record.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
4 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
23 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

IM
HOH logo
Imthetxarbi on High Arctic Overseas Holdings ·

Deep Value Multi Bagger Opportunity

Fair Value:CA$471.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative